- Home
- ACCS vs OTLK Comparison
ACCS vs OTLK Comparison
Compare ACCS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | OTLK |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 38.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ACCS | OTLK |
|---|---|---|
| Price | $9.73 | $0.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $3.83 |
| AVG Volume (30 Days) | 23.7K | ★ 13.1M |
| Earning Date | 11-11-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,646,000.00 | $1,413,535.00 |
| Revenue This Year | $0.18 | $1,578.49 |
| Revenue Next Year | $7.16 | $153.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.30 | N/A |
| 52 Week Low | $7.72 | $0.50 |
| 52 Week High | $13.35 | $3.39 |
Technical Indicators
Market Signals| Indicator | ACCS | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 25.67 |
| Support Level | $9.00 | $0.51 |
| Resistance Level | $11.34 | $0.56 |
| Average True Range (ATR) | 0.75 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 26.49 | 11.82 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.